SanjayGhare at 17:34, 27 March 2026

2026-03-27T17:34:44Z

New page

{{short description|Indian pharmaceutical company}}
{{Multiple issues|
{{More citations needed|date=January 2026}}
{{Tone|date=March 2026}}
}}
{{Use dmy dates|date=June 2022}}
{{Use Indian English|date=June 2022}}
{{Infobox company
| name = Laurus Labs Limited
| logo = Laurus Labs Logo.png
| logo_size =
| image_caption = Laurus Labs manufacturing facility in [[Visakhapatnam]]
| image = Laurus Labs Unit 3.jpg
| type = [[Public company|Public]]
| genre =
| traded_as = {{NSE|LAURUSLABS}}<br />{{BSE|540222}}
| predecessor =
| successor =
| foundation = {{start date and age|2005}}<ref>{{cite news |title=Laurus Labs Ltd |url=https://www.bloomberg.com/profile/company/LAURUS:IN |accessdate=17 April 2020 |work=Bloomberg}}</ref>
| founder = Satyanarayana Chava
| defunct =
| location_city = [[Hyderabad]], [[Telangana]]
| location_country = India<ref>{{cite news |title=Hyderabad-based Laurus Labs receives licence to manufacture 2DG |url=https://telanganatoday.com/hyderabad-based-laurus-labs-receives-licence-to-manufacture-2dg |access-date=27 January 2023 |work=Telangana Today |date=2 July 2021}}</ref>
| locations = 6
| area_served = Global
| key_people = {{ubl|
*Satyanarayana Chava (CEO)
*Vantaram Venkata Ravi Kumar (CFO)<ref>{{cite news |title=Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts |url=https://www.moneycontrol.com/news/business/companies/laurus-labs-banking-on-vertical-integration-to-crack-anti-hiv-tenders-and-us-formulations-mkts-4976561.html |accessdate=17 April 2020 |work=Moneycontrol}}</ref><ref>{{cite news |title=Laurus Labs: A hot startup in the pharma sector |url=https://www.forbesindia.com/article/hidden-gems/laurus-labs-a-hot-startup-in-the-pharma-sector/41063/1 |accessdate=17 April 2020 |work=Forbes India}}</ref>}}
| industry = [[Pharmaceuticals]]
| products = [[Pharmaceutical formulation|Formulations]]<br /> [[Active pharmaceutical ingredients]] Speciality Chemicals, Agro Chemicals
| services = Custom synthesis<br /> [[Contract development and manufacturing organization]]<br /> [[Fermentation]]
| revenue = {{increase}} {{INRConvert|6040|c}} (FY23)<ref name="fy23"/>
| operating_income =
| net_income = {{decrease}} {{INRConvert|796|c}} (FY23)<ref name="fy23">{{cite news |title=Laurus Labs Q4 net slumps |url=https://www.thehindu.com/business/laurus-labs-q4-net-slumps/article66785640.ece |access-date=27 June 2023 |work=The Hindu |date=27 April 2023 |language=en-IN}}</ref>
| assets =
| equity =
| owner =
| num_employees = 5,700 (2022)<ref>{{cite news |title=India's Laurus Labs says four employees died in fire incident |url=https://www.reuters.com/world/india/indias-laurus-labs-says-four-employees-dead-after-fire-incident-2022-12-27/ |access-date=27 January 2023 |work=Reuters |date=27 December 2022 |language=en}}</ref>
| parent =
| divisions =
| subsid = Laurus Synthesis {{Citation needed|date=March 2026}}
| homepage = {{URL|https://www.lauruslabs.com}}
| footnotes =
}}
'''Laurus Labs''' is an Indian multinational [[Pharmaceutical industry|pharmaceutical]] and [[biotechnology]] company headquartered in [[Hyderabad]]. Its focus areas include [[active pharmaceutical ingredients]] (APIs), [[Generic drug|generic formulations]], custom synthesis (CDMO), [[biotechnology]],<ref>{{Cite web|date=2020-11-27|title=Laurus Labs Share Price: Company forays into Lucrative Biotech Space|url=https://www.zeebiz.com/companies/news-laurus-labs-share-price-company-forays-into-lucrative-biotech-space-142066|access-date=2020-11-27|website=Zee Business}}</ref> veterinary APIs and [[agrochemical]]s. The company was founded in 2005 by Satyanarayana Chava.<ref>{{Cite web |last=Sharma |first=Neetu Chandra |title=How Satyanarayana Chava Grew Laurus Labs |url=https://www.businesstoday.in/magazine/corporate/story/how-satyanarayana-chava-grew-laurus-labs-326080-2022-03-15 |access-date=2022-03-29 |website=Business Today |date=15 March 2022 |language=en}}</ref>

Laurus Labs has its eight manufacturing plants located at [[Visakhapatnam]], [[Hyderabad]] and [[Bangalore]]. The manufacturing units have received one or more approvals from [[USFDA]], WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA.<ref>{{Cite news|last=Trivedi|first=Isha|title=Laurus Labs strikes gold by moving up the value chain. But there's a steeper climb ahead.|work=The Economic Times|url=https://economictimes.indiatimes.com/prime/pharma-and-healthcare/laurus-labs-strikes-gold-by-moving-up-the-value-chain-but-theres-a-steeper-climb-ahead-/primearticleshow/77515258.cms|access-date=2020-10-19}}</ref> The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers.{{citation needed|date=October 2020}} The R&D centres are based in Hyderabad, Visakhapatnam and United States.

== Business divisions ==
The company has 4 business divisions, which are [[generic formulation]] (FDF), generic [[Active pharmaceutical ingredient|APIs]], [[Contract development and manufacturing organization|contract development and manufacturing]] (CDMO)-Synthesis, [[biotechnology]]<ref>{{Cite web |date=2022 |title=Laurus Labs Limited: Annual Report 2021-22 |url=https://www.lauruslabs.com/Investors/PDF/Disclosures/LaurusLabsAnnualReportFY2021-22.pdf |access-date=16 June 2022 |website=Laurus Labs |page=3 }}</ref> and speciality chemicals.

=== Generic formulation (FDF) ===
In March 2020, Laurus Labs received US Food and Drug Administration approval to market [[hydroxychloroquine]] tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of [[COVID-19]].<ref>{{cite news |title=Coronavirus: Laurus Labs to supply Hydroxychloroquine for clinical trials in the US |work=Moneycontrol |url=https://www.moneycontrol.com/news/business/companies/coronavirus-laurus-labs-to-supply-hydroxychloroquine-for-clinical-trials-in-the-us-5082031.html |accessdate=17 April 2020}}</ref>

=== Generic APIs ===
Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest<ref>{{Cite web |last=Laurus Labs |title=Investor Presentation |url=https://www.lauruslabs.com/Investors/PDF/Q3/LaurusLabsFinancialResultsQ3FY2020InvestorPresentation.pdf }}</ref> HiPotent API capacities in India<ref>{{cite news |title=Laurus Labs eyes bigger play in generic formulations segment |work=Times of India |url=https://timesofindia.indiatimes.com/business/india-business/laurus-labs-eyes-bigger-play-in-generic-formulations-segment/articleshow/73001890.cms |accessdate=17 April 2020}}</ref> The company also makes [[Dolutegravir/lamivudine/tenofovir]], a medication for [[HIV/AIDS]],<ref>{{cite news |title=Laurus Labs gets USFDA nod for HIV drug |work=Economic Times Health |url=https://health.economictimes.indiatimes.com/news/industry/laurus-labs-gets-usfda-nod-for-hiv-drug/67821291 |accessdate=17 April 2020}}</ref><ref>{{cite news |title=Laurus Labs is ready to flood the US with cheap HIV drugs |work=Livemint |url=https://www.livemint.com/Industry/BvlKjOnhLgiHu1xbLqmiSP/Laurus-Labs-is-ready-to-flood-the-US-with-cheap-HIV-drugs.html |accessdate=17 April 2020}}</ref> and [[hydroxychloroquine]] tablets, which are used to treat certain types of [[malaria]].<ref>{{cite news |title=Laurus Labs gets USFDA nod for malaria tablets |work=The Hindu Business Line |url=https://www.thehindubusinessline.com/companies/laurus-labs-gets-usfda-nod-for-malaria-treatment-tablets/article26496219.ece |accessdate=17 April 2020}}</ref>

The company also manufactures oncology and cardiovascular APIs.<ref name=":1" /> Laurus Labs supplies (APIs) to nine of the 10 largest generic pharma companies in the world.<ref name=":1">{{Cite news |last=ET Bureau |date=29 March 2022 |title=ET Emerging Company of the Year 2021: Laurus Labs-A pharma company beats the virus trap to make it big |work=The Economic Times |url=https://economictimes.indiatimes.com/news/company/corporate-trends/emerging-company-of-the-year-laurus-labs-a-pharma-company-beats-the-virus-trap-to-make-it-big/articleshow/90481868.cms |access-date=2022-07-24}}</ref>

=== CDMO-Synthesis ===
Laurus Synthesis is the company's CDMO subsidiary.<ref>{{Cite news |last=Capital Market |first= |date=2021-01-12 |title=Laurus Labs arm incorporates wholly-owned unit |work=Business Standard India |url=https://www.business-standard.com/article/news-cm/laurus-labs-arm-incorporates-wholly-owned-unit-121011200273_1.html |access-date=2022-07-24}}</ref> The US, [[European Union]] and [[Japan]] are the three most important markets for Laurus Synthesis.<ref>{{Cite web |date=2022 |title=Laurus Labs Limited: Annual Report 2021-22 |url=https://www.lauruslabs.com/Investors/PDF/Disclosures/LaurusLabsAnnualReportFY2021-22.pdf |access-date=17 July 2022 |website=Laurus Labs |page=6 }}</ref>

=== Laurus Bio ===
Laurus Bio is the company's biotechnology subsidiary. Laurus Labs entered the biotechnology sector in 2020, by acquiring the Indian biotech company, Richcore.<ref name=":0">{{Cite web |last=Ramarathinam |first=Ashwin |date=2020-11-25 |title=Laurus Labs buys 73% stake in Biotech firm Richcore Lifesciences for Rs247 crore |url=https://www.livemint.com/companies/news/laurus-labs-buys-73-stake-in-biotech-firm-richcore-lifesciences-for-rs247-crore-11606311893776.html |access-date=2022-03-29 |website=mint |language=en}}</ref> Post the acquisition, Richcore was renamed to Laurus Bio Pvt Ltd, and became a subsidiary of Laurus Labs.<ref name=":0" /> As of 2022, Laurus Bio has put into operation a 180 [[Cubic metre|kilolitre]] fermentation capacity in food proteins.<ref>{{Cite web |publisher=NSE Website - Investors Presentation of the company |title=Investors Presentation of the company |url=https://archives.nseindia.com/corporate/LAURUSLABS_30012023120401_LaurusLabsFinancialResultsQ3FY2023InvestorPresentation.pdf |id=[https://www.nseindia.com/get-quotes/equity?symbol=LAURUSLABS Quotes] |website=www.nseindia.com/}}</ref><ref>{{Cite web |date=2022 |title=Laurus Labs Limited: Annual Report 2021-22 |url=https://www.lauruslabs.com/Investors/PDF/Disclosures/LaurusLabsAnnualReportFY2021-22.pdf |access-date=13 July 2013 |website=Laurus Labs |page=7 }}</ref>

== References ==
{{Reflist}}

==External links==
* {{Cite web|title=Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%|url=https://www.indiainfoline.com/article/news-top-story/laurus-labs-subsidiary-incorporates-laurus-ingredients-stock-gains-1-121011200323_1.html|access-date=2021-01-20|website=www.indiainfoline.com|language=en}}
* {{Cite news|date=3 May 2021|title=Laurus Labs: Diversification to speed up in FY23; add on declines|work=Moneycontrol|url=https://www.moneycontrol.com/news/business/moneycontrol-research/laurus-labs-diversification-to-speed-up-in-fy23-add-on-declines-6847661.html|access-date=3 May 2021}}
* {{Cite web|date=4 May 2021|title=Laurus Labs is already halfway past its $1 billion revenue target and has new capacities and products to back up its growth plan|url=https://www.moneycontrol.com/news/opinion/laurus-labs-1-billion-sales-target-needs-a-bit-of-luck-on-execution-6851581.html|access-date=4 May 2021|website=Moneycontrol}}

{{Nifty 200 companies}}

[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies established in 2005]]
[[Category:Manufacturing companies based in Hyderabad, India]]
[[Category:2005 establishments in Andhra Pradesh]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]

Laurus Labs - Revision history

SanjayGhare at 17:34, 27 March 2026